Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Carbon Dioxide · 1 trial · 1 indication
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked as part of screening survey prior to concept viewing. If the participant answered "I do not purchase any product to relieve congestion" the participant was excluded. Participants could select only one option available.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first use. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after the first dose of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option. It was done to compare the spray with the product selected by the participant in Q1. There were 11 points between the two products that participants could divide anyways thet wanted (11-0, 10-1, 9-2, 8-3, 7-4 or 6-5 etc). The more the participant liked a product compared to other, the higher the number of points were to be given to that product.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which was divided into 3 parts: screening survey, after product trial questions, and at home usage experience.This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
There was one questionnaire used in this study which is divided into 3 parts: screening survey, after product trial questions, and at home usage experience. This question was asked after at-home use of the product. Participants could select only one option.
A score of 1 indicates that the statement does not apply at all to the product that you used. A score of 7 indicates that it applies completely to it. You can use any score from 1 to 7 to indicate how much or how little you think the statement applies to this product
| Arm | Type | Description |
|---|---|---|
| Treatment Group | EXPERIMENTAL | Participants will receive one dose of nasal carbon dioxide (CO2) in the study clinic under medical supervision, followed by an additional six days of at home use, up to 4 times per day. |
| Name | Type | Description |
|---|---|---|
| Carbon Dioxide | DRUG | Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds |
Inclusion Criteria: * Participant who demonstrate understanding of, and willingness to participate in the study * Aged at least 18 years. * Understands and is willing, able and likely to comply with all study procedures and restrictions. * Good general and mental health with, in the opinion of the ...
Carbon dioxide is being developed by GSK plc as a nasal spray for nasal congestion. It is in Phase 2 clinical development in the ENT therapeutic area. The completed Phase 2 trial NCT02113449 studied 147 adults with nasal congestion in the United States. It is investigational and not approved.
Carbon dioxide is designed to inhibit GSK3A, GSK3B, and IMPA1. These targets belong to the inhibitor class. By acting on these molecular targets, the small molecule formulation is intended to address nasal congestion. The precise downstream effects on congestion have not been established in the completed Phase 2 study.
GSK plc, which trades under the ticker GSK, is developing carbon dioxide as a nasal spray for nasal congestion. The company is the sponsor of the Phase 2 program. No partnership or licensing details for this asset have been disclosed.
Carbon dioxide is in Phase 2 development for nasal congestion. The only listed trial, NCT02113449, is completed and enrolled 147 participants. There are no active trials at this time. The asset remains investigational and has not been approved by the FDA.
Carbon dioxide has been studied in one completed Phase 2 trial, NCT02113449, titled Market Potential of Carbon Dioxide Nasal Spray. It enrolled 147 adults aged 18 years and older of all sexes with nasal congestion in the United States. The trial was uncontrolled, non-randomized, and not blinded.